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Neurobiology of Disease

Low Doses of Memantine Disrupt Memory in Adult Rats
Catherine Creeley,1,2* David F. Wozniak,1* Joanne Labruyere,1 George T. Taylor,2 and John W. Olney1*
Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, and 2Department of Psychology, University of Missouri,
St. Louis, Missouri 63121
1

Memantine, a drug recently approved for treatment of Alzheimer’s disease, has been characterized as a unique NMDA antagonist that
confers protection against excitotoxic neurodegeneration without the serious side effects that other NMDA antagonists are known to
cause. In the present study, we determined what dose of memantine is required to protect the adult rat brain against an NMDA receptormediated excitotoxic process and then tested that dose and a range of lower doses to determine whether the drug in this dose range is
associated with significant side effects. Consistent with previous research, we found that memantine confers a neuroprotective effect
beginning at an intraperitoneal dose of 20 mg/kg, a dose that we found, contrary to previous reports, produces locomotor disturbances
severe enough to preclude testing for learning and memory effects. We then determined that, at intraperitoneal doses of 10 and 5 mg/kg,
memantine disrupts both memory and locomotor behaviors. Rats treated with these doses performed at control-like levels in learning a
hole-board task but were significantly impaired in demonstrating what they had learned when tested 24 h later. This impairment of
memory retention was not state dependent in that it was demonstrable regardless of whether the rats were or were not exposed to
memantine on the day of retention testing. We conclude that, in the adult rat, memantine behaves like other NMDA antagonists in that it
is neuroprotective only at doses that produce intolerable side effects, including memory impairment.
Key words: memantine; neuroprotection; memory impairment; locomotor impairment; kainic acid; NMDA antagonists

Introduction
It is well established that glutamate excitotoxicity triggers neurodegeneration in acute brain injury conditions such as stroke, status epilepticus, and head trauma. Drugs that block NMDA glutamate receptors are known to be neuroprotective in animal
models for studying these acute brain injury conditions (Olney,
1989; Choi, 1992a,b; Lipton and Rosenberg, 1994). Efforts to
develop NMDA antagonist drugs for treatment of acute brain
injury in humans have been uniformly unsuccessful because
doses required for neuroprotection produce a variety of adverse
side effects, ranging from acute psychotic manifestations in humans (Herrling, 1992; Krystal et al., 1994) to neuronal injury,
locomotor impairment, and memory dysfunction in animals
(Olney et al., 1989, 1991; Allen and Iversen, 1990; Wozniak et al.,
1990, 1998; Fix et al., 1993; Hargreaves et al., 1993).
It has been proposed that a chronic low-grade excitotoxic
mechanism may underlie the neurodegenerative process in Alzheimer’s disease (AD), and this has kindled interest in the possibility that NMDA antagonists might arrest neurodegeneration
and prevent cognitive deterioration in AD (Danysz and Parsons,
2003; Lipton, 2004a,b). Memantine has become recognized in
recent years as an NMDA antagonist that is well tolerated by
humans at doses that putatively are neuroprotective against excitotoxic neurodegeneration. It has been described as an agent that
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has unique NMDA receptor binding kinetics that enable it to
confer neuroprotective therapeutic benefits in the absence of
neurotoxic or behavioral side effects (Chen et al., 1998; Danysz
and Parsons, 2003). However, the experimental designs used in
previous studies have not allowed for a full evaluation of the
possible behavioral side effects of this drug at neuroprotective
doses. Extensive research testing other NMDA antagonists in animal experiments has shown that these drugs cause neurobehavioral side effects, including both memory and locomotor disturbances, at doses substantially lower than are required for
neuroprotective effects. Presumably, this signifies that only a
slight degree of NMDA receptor blockade is required for neurobehavioral impairment, whereas a much greater degree is required to achieve neuroprotection. Regardless of where the truth
lies in this theoretical debate, it is a practical fact that memantine
was recently approved by the Food and Drug Administration
(FDA) for treating patients with moderate to advanced Alzheimer’s disease and is currently being widely marketed for this
purpose. FDA approval was based on both preclinical studies
describing neuroprotective effects in rats at doses reportedly free
from side effects (Chen et al., 1998; Danysz and Parsons, 2003)
and human clinical trials providing evidence for modest functional benefits at doses that were well tolerated by patients with
Alzheimer’s disease (Reisberg et al., 2003; Tariot et al., 2004).
The present study was undertaken to see whether we could
confirm in adult rats that memantine is uniquely different from
other NMDA antagonists. That is, does it have neuroprotective
effects in the adult rat brain at doses that do not produce sensorimotor or memory disturbances? To address this question, we
administered kainic acid (KA) to adult rats in a dose sufficient to
trigger a seizure-related brain damage (SRBD) syndrome that
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NMDA antagonist drugs are known to protect against and determined what dose of memantine is required to provide significant
protection. In other experiments, we administered memantine to
adult rats, using doses at or below the dose required for neuroprotection, and evaluated the effects of these several doses on
activity and sensorimotor performance and on tests of spatial
memory acquisition and retention.

Materials and Methods
Animals. Adult Sprague Dawley female rats 6 to 8 months of age (270 –
363 g weight range) were used because female rats are more sensitive than
males to adverse side effects of NMDA antagonists (Olney et al., 1989; Fix
et al., 1995; Jevtovic-Tedorovic et al., 2001). All rats were housed in
polypropylene cages with wood-chip bedding (three rats per cage) for the
duration of the experiments and were maintained on a 12 h light/dark
schedule in a temperature- and humidity-controlled room. With the
exception of those placed on food restriction, all animals were given
access to food and water ad libitum. All experimental procedures were
approved by the Animal Studies Committee of the Washington University School of Medicine.
Model for evaluating neuroprotective effects of memantine. To study the
ability of memantine to protect against excitotoxic neurodegeneration,
we used an excitotoxicity model in which rats are treated intraperitoneally with a dose of KA (12 mg/kg) that reliably triggers status epilepticus
and an SRBD syndrome. When this dose of KA is administered to adult
rats, it activates kainate receptors, which are highly concentrated in the
CA3 region of the hippocampus. This excitatory stimulus is then propagated via the Shaffer collateral pathway to CA1 hippocampal pyramidal
neurons and then via these neurons to extrahippocampal neurons that
comprise a seizure-prone circuit within which the excitatory activity
feeds on itself in a circular and reverberating pattern for several hours
until many neurons within the circuit die from excitotoxic overstimulation. Although the syndrome is triggered by hyperactivation of kainate
receptors, the seizure activity is propagated primarily though NMDA
receptors. Therefore, the seizures can be arrested and the SRBD prevented by
drugs that block NMDA receptors (Clifford et al., 1990). Thus, this is an
excellent in vivo model for testing the efficacy of an NMDA antagonist drug
in protecting against excitotoxic neurodegeneration. Various NMDA antagonists that have been tested in this model, including (⫹)-5-methyl-10,11dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate (MK-801) and
phencyclidine (PCP), act at the same site within the NMDA receptor ion
channel as memantine. These agents typically arrest the seizure activity completely and prevent all manifestations of brain damage except for an acute
edematous swelling of cell bodies and neuropil elements in the CA3 hippocampal region, in which KA directly exerts excitotoxic activity that is not
blocked by the NMDA antagonist. Because CA1 hippocampal neurons are
the first neurons in the path of propagation of this SRBD syndrome, a
reliable and efficient method for evaluating the degree of neuroprotection conferred by an NMDA antagonist is to compare the SRBD manifestations in the CA3 and CA1 regions of the hippocampus. If the NMDA
antagonist is effective, the neuropathological reaction in the CA3 region
will not be diminished, but, in the CA1 region, it will be reduced to a
degree commensurate with the efficacy of the NMDA antagonist in protecting against NMDA receptor-mediated excitotoxicity.
To determine whether memantine effectively protects against the KAinduced SRBD syndrome, rats were treated with KA alone (12 mg/kg; n ⫽
14) or this dose of KA plus memantine (10 mg/kg, n ⫽ 6; 20 mg/kg, n ⫽
10) and observed for seizure-related behaviors for 4 h, anesthetized, and
killed by perfusion fixation, and their brains were examined in the CA3
and CA1 regions for evidence of acute SRBD. Our research design called
for testing memantine initially at a dose of 20 mg/kg, and, if this dose of
memantine was neuroprotective, additional doses were to be tested, each
being one-half of the immediately preceding dose, until a dose was found
that provided no neuroprotection. It was only necessary to test two doses
because the first dose (20 mg/kg) provided significant neuroprotection
and the next lower dose (10 mg/kg) did not. We chose 20 mg/kg as the
initial dose because this is the dose that others have reported is effective in
protecting the adult rat brain against excitotoxic neurodegeneration
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(Wenk et al., 1994; Misztal et al., 1996; Danysz et al., 1997; Chen et al.,
1998). Control animals for these experiments consisted of rats treated
with saline (n ⫽ 3) or memantine at 10 (n ⫽ 6) and 20 (n ⫽ 6) mg/kg
intraperitoneally. All agents were administered by intraperitoneal injection. Memantine hydrochloride (Sigma, St. Louis, MO) and kainic acid
(Ocean Produce, Shelburne, Nova Scotia, Canada) were both dissolved
in distilled water and adjusted with NaOH to a pH of 7.4.
Histopathology. Four hours after treatment, the animals were deeply
anesthetized with chloral hydrate and perfused transcardially with a heparinized saline flush, followed by a fixative containing 2.5% paraformaldehyde and 1.5% glutaraldehyde in a 0.1 M sodium phosphate buffer. The
brains were then sliced into 1 mm transverse slabs, placed in osmium
tetroxide overnight, dehydrated in alcohol, cleared in toluene, and embedded in Araldite. Using an ultramicrotome, the brains were sectioned
coronally at 1 m and floated onto slides for staining with methylene
blue/azure II. For evaluation of the histopathological reaction, sections
were chosen from a rostrocaudal level at which the corpus callosum
ceases decussating [bregma ⫺5.50 mm (Paxinos and Watson, 1998)]. At
this level, the hippocampal formation is displayed to its fullest extent,
including both dorsal and ventral aspects.
Quantitative evaluation of the SRBD reaction. Two trained histologists
unaware of treatment condition examined the CA3 and CA1 regions of
the hippocampus and assigned severity of damage scores on a scale of 0
(no pathology) to 4 (severe pathology). Criteria for assessing damage
were the percentage of the pyramidal row of neurons displaying changes
and the magnitude and type of changes. Typically dendritic processes and
both neuronal and glial cell bodies show edematous swelling to a mild,
moderate, or severe degree, and, when the reaction is most severe, it
includes pyknotic changes in the nucleus of the affected neurons. All of
these changes were factored into the brain damage score. The brain damage score of the two independent raters were averaged to obtain a single
score for each of the brain regions (CA3 and CA1) of each animal, and the
mean values for each region and each condition were determined. Calculation of Pearson’s r showed that the inter-rater reliability between the
two sets of scores was significant (r ⫽ 0.70; p ⬍ 0.0005; Spearman’s 
showed a similar degree of correlation).
Behavioral studies. Dose–response studies were conducted to determine the effects of memantine on locomotor activity, sensorimotor function, and spatial learning and memory as described below. Separate cohorts of naive rats were used for each study.
Locomotor activity test. To test the effects of memantine on locomotor
activity, rats were randomly assigned to receive an injection of saline (n ⫽
22) or memantine at an intraperitoneal dose of 2.5, 5, 10, or 20 mg/kg
(n ⫽ 6 – 8 per dose). Immediately after injection, each animal was allowed to freely explore a standard (44 ⫻ 24 ⫻ 21 cm) empty polystyrene
rat cage and was continuously monitored for 90 min. The cage was surrounded by a 25 ⫻ 45 cm frame containing a 4 ⫻ 8 matrix of photocell
pairs located along the x- and y-axes of the outside of each cage. Another
frame, containing four photocell pairs along the length of the cage elevated 16.5 cm above the floor (z plane), recorded rearing events. The
output of the photocells was fed to an on-line computer. Total ambulations, fine movements, and rearing events were quantified by system
software (MotorMonitor; Hamilton-Kinder, Poway, CA). Total ambulations were defined as the number of times the animal changed its
whole-body position, as measured by the breaking and clearing of two
sequential pairs of photobeams horizontally along the x- and y-axes. Fine
movements were defined as the number of times the animal moved
without changing its whole-body position, measured by the breaking and
clearing of a single pair of photobeams without ambulating and generally
corresponds to small movements such as grooming or head shaking.
Quantification of fine movements has also been used to estimate levels of
stereotypical behaviors induced by NMDA antagonists, such as PCP,
using the same behavioral testing system (Swanson and Schoepp, 2002).
Rearing events were defined as the number of vertical beam breaks along
the z plane. The activity data were accumulated in 10 min bins. An a
priori decision was made to restrict our assessment of activity measures
to four posttreatment intervals (10, 30, 60, and 90 min) to maintain
adequate statistical power for evaluating drug effects at meaningful posttreatment times.
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Sensorimotor battery. To evaluate the effects of memantine on sensorimotor function, groups of rats were randomly assigned to receive an
injection of saline or memantine at 2.5, 5, 10, or 20 mg/kg intraperitoneally (n ⫽ 12 per group). Performance was assessed using four tests that
were part of a larger battery of tests shown to be useful for detecting acute
drug-induced disturbances in different aspects of sensorimotor function
(initiation of movement, coordination, balance, and strength) after administration of another NMDA antagonist (MK-801) in rats (Wozniak et
al., 1990). The maximal trial length was 60 s. Testing began at 30 min after
injection and was conducted in sequence as follows. (1) For “walking
initiation,” each rat was placed in the center of a square (30 ⫻ 30 cm)
outlined by white tape in the middle of a smooth black table top (73 ⫻
103 cm). Latency to move all four paws outside the boundary of the
square was recorded. (2) For the “beam,” each rat was placed on a narrow
wooden beam (70 ⫻ 2.5 ⫻ 49 cm high) and allowed 60 s to traverse its
length. Latency to fall was recorded. Performance on the beam was also
scored using a 0 (immediate fall) to 5 (easily and completely traversed in
both directions) scale. (3) For the “platform,” each rat was placed onto a
platform located atop a pole (7.5 ⫻ 15 ⫻ 63 cm high). Latency to fall from
the platform was recorded. (4) For the “90° inclined screen,” each rat was
placed on a wire mesh grid (54 ⫻ 35 cm; 1 cm squares) inclined to 90°
relative to an elevated table top. They were placed on the middle of the
screen, head down. Latency to turn 180° and climb to the top of the
screen was recorded.
Side effects index. To characterize dose-dependent side effects of memantine, we developed a global scale based on the number of activity and
sensorimotor measures that showed significant differences (less than
Bonferroni’s corrected levels) between a memantine dose group and
saline controls. For the sensorimotor measures (walking initiation, beam
latency, beam performance, platform, and inclined screen), a memantine
dose group received a score of 1 if it was significantly different from the
saline control group. For example, with regard to beam performance
scores, the 5, 10, and 20 mg/kg memantine groups were each significantly
different from the saline control group, so each memantine group received a score of 1 for beam performance. For the activity measures (total
ambulations, fine movements, and rearings), a memantine dose group
received a score of 1 if that group was significantly different from saline
controls on at least two of the four time periods of the test session. The
scores were summed across the eight measures to yield a “side effects
index” value.
Hole-board test of spatial learning and memory. The rotating holeboard task (Brosnan-Watters and Wozniak, 1997) was used to assess the
effects of memantine on spatial learning and memory. The procedure
used was directly adapted from a protocol developed for studying the
effects of MK-801 on acquisition and retention of an appetitive spatial
task in mice (Wozniak et al., 1996; Brosnan-Watters and Wozniak,
1997). Specifically, it is a reference-memory-based task shown to be sensitive for documenting acute impairments after a low dose of MK-801
(Brosnan-Watters et al., 1996) as well as long-term deficits resulting from
neurotoxic doses of MK-801 (Wozniak et al., 1996). It involves training a
rodent to poke its head into a hole and retrieve food reinforcement from
a “baited” hole that contains a reinforcer on every trial. An animal is
required to learn the spatial location of a baited hole in a single session,
and a retention test is administered 24 h later.
The apparatus consisted of a square floor that contained a hole in each
of the four corners and was enclosed by Plexiglas sides. Each hole contained a reinforcer consisting of a single piece of Post Fruity Pebbles
cereal, which was made inaccessible by being placed under a screen at the
bottom of a hole. The screen allowed the odor of the food (bait) to
emanate from the hole but prevented access to it. When an individual
hole was baited, a piece of cereal was placed on top of the screen, making
the food accessible. The apparatus was placed on a turntable so that it
could be rotated between trials during acquisition and retention sessions.
Rats were handled, food restricted to 85–90% of their baseline ad libitum
body weights, habituated to the apparatus and start tube, and trained to
poke their heads into the exposed holes to retrieve the reinforcer. Fiftyone female naive rats were then randomly assigned to the following treatment groups: saline (n ⫽ 10) or memantine at 2.5 mg/kg (n ⫽ 10), 5
mg/kg (n ⫽ 12), or 10 mg/kg (n ⫽ 19). Our experimental design origi-
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nally included memantine at 20 mg/kg, but this dose so incapacitated the
rats that none could perform the test. Unequal numbers were assigned to
the memantine groups because we observed in pilot studies that some
animals injected with memantine at doses lower than 20 mg/kg were
likely to be dropped from testing for failure to perform (defined below).
Therefore, the size of the memantine groups was increased to adjust for the
potential loss of animals in those groups. For each experiment, the rats were
weighed and injected with saline or memantine 30 min before the beginning
of acquisition training. Each rat was randomly assigned to a baited hole
location that remained the same for that rat throughout testing.
At the beginning of each acquisition trial, a rat was placed into an
opaque plastic start tube, open at both ends, which was positioned in the
center of the board. The tube was then removed, allowing the rat to begin
exploration of the apparatus and poke its head into the holes until it
retrieved the food reinforcer. Immediately after consuming the reinforcer, the rat was placed back into the start tube, the board was rotated
90° on a pseudorandom basis, and the procedure was repeated. A trial
ended when the food reward was consumed or 3 min elapsed. Rotation of
the hole board before each trial prevented rats from using odor (“scent
trails”) or other proximal cues to locate the correct hole. The floor of the
hole board was cleaned of urine and/or feces between trials. The repeated
masking of old trails with new, along with the rotation of the board, was
used to control for odor cues. For a given trial (except the first), the baited
hole containing the reinforcer was different from the one used on the
previous trial, although it was always located in the same relative spatial
position whereby the baited hole was associated with the same distal cues.
A trial was counted as correct only when the rat moved directly to, and ate
from, the baited hole without poking its nose into any other hole on the
board. An error was recorded if the rat poked its nose into an unbaited
hole. A trial was recorded as failed if the animal did not find and consume
the food reward in the 3 min time period. A rat that scored five consecutive failed trials in a row was dropped from additional testing for failure
to perform. The rats were trained using a massed-trials protocol in which
the above-described trials were repeated until they reached an a priori
criterion of eight correct trials of nine consecutive trials. The total number of trials-to-criterion and errors committed in reaching criterion were
recorded and served as dependent variables. A retention test was conducted 24 h after the acquisition session to evaluate the extent to which
the mice retained what they had learned on the previous day. The protocol used during retention testing was the same as that used during acquisition except that no drug or saline was administered.
Hole-board test for state dependency. After the completion of the learning and memory experiments outlined above, a second hole-board experiment was conducted to test for possible state-dependent memory
effects. A total of 22 rats were assigned to receive injections of saline (n ⫽
8) or memantine (10 mg/kg; n ⫽ 14) before both acquisition and retention test sessions. The rats were injected 30 min before acquisition and
retention test sessions. The procedures for this experiment were identical
to those outlined in the previous hole-board experiments, with the exception that the rats were treated before both acquisition and retention
testing to evaluate possible state-dependent effects.
Statistical analyses. In general, the data were analyzed though the use of
ANOVA models. Some models were one-way ANOVAs involving saline
and various drug dosage groups. This type of ANOVA was used to evaluate the neuroprotective effects of memantine after KA administration.
We felt this was a reasonable model to use because our severity of damage
scale was continuous in nature and comprised equal intervals. Although
the scale had a maximal assigned value, we felt that, given the design of
our experiment, it was unlikely that this would lead to ceiling effects.
Another ANOVA model often used on the behavioral data included one
between-subjects variable (treatment groups) and usually one withinsubjects variable, such as blocks of trials or time periods. When ANOVAs
with repeated measures were conducted, the Huynh-Feldt adjustment of
degrees of freedom was used for all within-subjects effects containing
more than two levels to generate appropriate p values to help protect
against violations of the sphericity/compound symmetry assumptions
underlying this ANOVA model. Bonferroni’s adjustment was used to
maintain familywise ␣ at 0.05 when multiple comparisons were
conducted.
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Results
Neuroprotective effects of memantine
All animals treated with KA, regardless of
whether they also received memantine,
displayed behavioral automatisms of the
type characteristically observed in KAtreated rats (Lothman and Collins, 1981).
In the 30 – 45 min posttreatment period,
they showed preconvulsive behaviors consisting primarily of staring spells and wetdog shakes. By 60 –90 min, additional
automatisms were manifested with increasing frequency, including facial
twitching, eye blinking, chewing, and head
nodding. By 120 min, they were displaying
conspicuous repetitive convulsive behaviors consisting of forelimb clonus, rearing
on hindlimbs in a “praying” stance, loss of
balance, falling, and copious salivation.
Although there were individual differences in the rate at which these behaviors
progressed, the rate of progression and severity of behavioral manifestations were
similar for the KA-alone and KA plus memantine groups. Thus, in terms of seizure- Figure 1. Appearance of the CA1 and CA3 hippocampal regions 4 h after treatment with 20 mg/kg memantine (Mem) or 12
related behaviors, there was no apparent mg/kg KA, either alone or together with 10 or 20 mg/kg memantine. After treatment with memantine alone at 20 mg/kg, both the
protective effect of memantine. This is in CA1 and CA3 regions have a normal appearance (identical to saline controls; data not shown). After 12 mg/kg KA, there is an acute
contrast to previously reported results edematous reaction affecting dendritic and glial processes and cell bodies in both the CA1 and CA3 regions. The severity of this
KA-induced reaction is not appreciably modified in either the CA1 or CA3 regions by 10 mg/kg memantine. Memantine at 20 mg/kg
with other NMDA antagonists, such as
conferred no protection in the CA3 region but did reduce the severity of the reaction in the CA1 region.
MK-801, which completely suppresses behavioral manifestations of KA-induced
seizure activity (Clifford et al., 1990). For a detailed description of
the behaviors manifested in animals treated with various doses of
memantine alone, see below.
Histopathological evaluation of the brains 4 h after treatment
revealed a severe degree of SRBD in both the CA3 and CA1 regions of the hippocampus in 100% of animals treated with KA
alone (Fig. 1). The pathological changes consisted of conspicuous
edematous swelling of dendritic endings and of specific neuronal
and glial cell bodies, with clumping of nuclear chromatin in some
neuronal profiles. The pattern and nature of these changes were
identical to descriptions that have been reported previously in
KA-treated rats (Olney, 1985; Clifford et al., 1990).
A significant one-way ANOVA showed that memantine treatment significantly affected the severity of damage in the CA1
region of the hippocampus (F(2,27) ⫽ 16.84; p ⬍ 0.0005). Subsequent pairwise comparisons revealed that, compared with the
KA-alone group, the 20 mg/kg group showed significantly less
severity of damage. The 10 mg/kg dose, however, did not significantly reduce severity of damage ( p ⬍ 0.0005) (Fig. 2). Memantine did not completely prevent CA1 hippocampal tissue damage
in any animal compared with saline controls. These results are
consistent with the observation that memantine also did not effectively prevent seizure activity in any animal. A nonsignificant
Figure 2. Group mean severity of damage scores for the CA3 and CA1 subfields of the hippocampus showing that animals (n ⫽ 10) pretreated with 20 but not 10 mg/kg memantine
ANOVA for the CA3 data showed that the memantine treatment
(Mem) had significantly lower severity of damage scores in the CA1 region compared with those
did not affect severity of damage in this brain region at either dose
treated with KA alone (n ⫽ 14). Neither dose of memantine provided neuroprotection in the
(Fig. 2). Seizures and SRBD changes were not observed in any of
CA3 field.
the rats treated with saline or memantine alone.
General behavioral responses to memantine
During several of the behavioral tests, an experimenter who was
unaware of the drug treatment status of individual animals recorded observations concerning the general posttreatment be-

havioral responses. After memantine injections, rats initially appeared lethargic and “dazed” in that they seemed less reactive to
environmental stimuli compared with controls. Gradually,
memantine-treated rats began displaying a combination of hy-
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Table 1. ANOVA summary from activity test
Variable

Effect

df

F

p

Simple main effects

Total ambulations

Group
Time
Group ⫻ time
Group
Time
Group ⫻ time
Group
Time
Group ⫻ time

4, 45
3, 35
12, 135
4, 45
3, 35
12, 135
4, 45
3, 35
12, 135

1.93
46.14
18.80
8.31
28.40
24.59
6.65
36.06
9.92

0.12
0.0005
0.0005
0.0005
0.0005
0.005
0.0005
0.0005
0.005

10*, 60*, 90*

Fine movements

Rearings

10*, 30*, 60*, 90*
10*, 30†, 60*, 90*

*p ⬍ 0.0125, Bonferroni’s corrected level; †p ⬍ 0.05.

Figure 3. Group means for total ambulations, fine movements, and rearings across time after treatment with saline or 2.5, 5,
10, or 20 mg/kg doses of memantine. a, For total ambulations (whole-body movements), animals treated with 10 or 20 mg/kg
showed significant (*) hypoactivity at the beginning of the test compared with saline controls. The numbers of total ambulations
steadily decreased throughout the remainder of the test session in the saline and 2.5 and 5 mg/kg memantine Mem) groups. In
contrast, the 10 and 20 mg/kg memantine groups showed progressive increases in activity, the latter group being significantly
higher than saline controls at both 60 and 90 min, and the former only at 90 min. b, Memantine produced similar changes in
activity levels with regard to fine movements, except that differences were more extreme between the 10 and 20 mg/kg memantine groups and saline controls at the later time points, and the 5 mg/kg memantine group had significantly fewer fine movements
compared with saline controls at 10 min after treatment. c, The three lowest doses of memantine significantly decreased rearing
at 10 min after treatment compared with the saline controls, although all four groups exhibited similar levels of decreased rearing
throughout the rest of the test period. Numbers of rearings remained relatively high throughout the test session in the animals
treated with 20 mg/kg memantine such that they showed significantly elevated levels at 60 and 90 min after treatment. *p ⬍
0.0125, Bonferroni’s corrected level.

peractive, stereotypical, and ataxic motor behaviors. These behaviors included head wagging, backward walking, and a waddling gait secondary to both trunkal and limb ataxia. These druginduced behaviors were most extreme and frequent in the 20
mg/kg memantine group and appeared to decrease in a dosedependent manner (see side effects index below), although some
ataxic tendency appeared to be present after 10 and 5 mg/kg
doses.
Locomotor activity
In rats treated with 0, 2.5, 5, 10, and 20 mg/kg memantine, data
for the activity parameters (total ambulations, fine movements,
and rearing) were assessed for statistical significance at 10, 30, 60,
and 90 min after treatment. A summary of the statistical results is
listed in Table 1.
Total ambulations
In untreated control rats, total ambulations were markedly increased at 10 min after treatment (hyperactive response to an
unfamiliar environment) but decreased dramatically by 30 min
and continued to decrease for the remaining 60 min test period
(Fig. 3a). There was a dose-related suppression of total ambulations in the memantine groups at 10 min after treatment. How-

ever, in the 30 –90 min interval, the 10 and
20 mg/kg memantine groups became progressively more hyperactive. This effect
became most prominent at 90 min and
was more pronounced with the 20 mg/kg
dose (Fig. 3a). These trends were supported by an ANOVA and accompanying
contrasts conducted on these data. Specifically, a significant main effect of time and
a significant group ⫻ time interaction indicated that performance changed over
time, with the extent of change dependent
on the treatment group. Significant simple
main effects were found at 10, 60, and 90
min, showing that the groups differed significantly in performance at these time
points (Table 1). At 10 min after treatment, the saline controls were hyperactive
relative to the 5, 10, and 20 mg/kg memantine groups ( p ⫽ 0.016, 0.001, and 0.0005,
respectively). In contrast, the 20 mg/kg
memantine rats were significantly more
active than saline controls at 60 min,
whereas both the 10 and 20 mg/kg memantine groups were significantly more
active than the controls at 90 min after
treatment ( p ⫽ 0.0005).

Fine movements
The effects of memantine on fine movements were very similar to the effects on
total ambulations. In untreated control
rats, fine movements were markedly increased at 10 min after treatment but decreased dramatically over the first 30 min
and continued to decrease throughout the
remaining test period. Memantine treatment caused deviations from this normal
pattern of fine movements whereby there
was a suppression of fine movements at 10
min after treatment in animals treated with the three highest
doses of memantine (5, 10, and 20 mg/kg) compared with saline
controls. However, in the 30 – 60 min interval, there was a crossover from hypoactive to hyperactive for animals treated with 10
or 20 mg/kg doses of memantine. This effect became progressively more extreme in the 60 –90 min interval (Fig. 3b). An
ANOVA of these data yielded significant main effects of group
and time and a significant group ⫻ time interaction, showing
that the performance of the treatment groups differed over time
(Table 1). Significant simple main effects were found at each of
the posttreatment time periods, indicating that group performances differed at those times. Pairwise comparisons conducted
at 10 min after treatment confirmed that the saline controls exhibited significantly more fine movements than the 5, 10, and 20
mg/kg memantine groups ( p ⫽ 0.001, 0.0005, and 0.0005, respectively). Additional pairwise comparisons conducted within
each time period showed that the number of fine movements
were significantly increased in the 20 mg/kg memantine group
relative to saline controls for the 30, 60, and 90 min posttreatment
times ( p ⫽ 0.001, 0.005, and 0.005, respectively). Numbers of
fine movements were also significantly increased in the 10 mg/kg
memantine group relative to controls at 60 and 90 min after
treatment ( p ⫽ 0.001 and 0.0005, respectively).
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Rearing
Memantine at 20 mg/kg induced relatively
high levels of rearing at the beginning of
the test session, which remained high
throughout the 90 min posttreatment period. In contrast, the other memantinetreated rats showed an initial suppression
of rearing at 10 min. However, their levels
and those of saline controls decreased and
were essentially equivalent for the remainder of the test session (Fig. 3c). An
ANOVA of the rearing data revealed significant main effects of group and time
and a significant group ⫻ time interaction, indicating that group performances
differed over time (Table 1). Significant
simple main effects were found at each of
the posttreatment time periods, showing
differences among groups at each point.
Pairwise comparisons conducted at 10
min confirmed that the saline controls exhibited significantly more rearings than
the 2.5, 5, and 10 mg/kg memantine
groups ( p ⫽ 0.003, 0.001, and 0.0005, respectively). Additional pairwise comparisons conducted within each time period
showed that the number of rearings was
significantly increased in the 20 mg/kg
memantine group relative to saline controls at 60 and 90 min after treatment
( p ⫽ 0.005 and 0.005, respectively).

Figure 4. Effects of memantine on a battery of sensorimotor tests. a, The results of the walking initiation test showing
dose-dependent effects on performance. Animals in the 20 mg/kg memantine group took significantly (*) longer to initiate
movement out of the square compared with the saline controls. The 5 and 10 mg/kg memantine groups took substantially ( p ⬍
0.05) longer to move out of the square compared with the saline control group, although p values were not less than the
Bonferroni’s corrected level ( p ⫽ 0.0125). b, Latency to fall from the beam was also found to be dose dependent. Memantine at
2.5, 5, and 20 mg/kg significantly (*) decreased the time the animals were able to remain on the beam. c, Beam performance
scores showed similar results, with the 5, 10, and 20 mg/kg memantine groups showing significantly lower scores compared with
saline controls. The platform (d) and 90° inclined screen (e) tests revealed a significant effect of memantine treatment attributable
mainly to the extremely poor performance of the 20 mg/kg group, which was significantly impaired relative to the saline controls.
The performance of all of the other memantine groups was not significantly different from that of the saline-treated groups for
either measure. f, The side effects index showed a continuum of dose-dependent side effects from memantine administration. The
20 mg/kg dose produced significant impairment on every measure, whereas the 2.5 mg/kg dose produced significant performance
deficits in only one of eight measures. The 5 and 10 mg/kg doses of memantine produced an intermediate level of side effects.
*p ⬍ 0.0125, Bonferroni’s corrected level; 0.0125 ⬍ †p ⬍ 0.05.

Sensorimotor battery
Because gross differences in body weight
can affect performance in certain sensorimotor tasks, we conducted a one-way
ANOVA to test for possible differences in
body weight among the treatment groups.
The results showed no significant differences between groups for mean body weight. The results of the
walking initiation test (Fig. 4a) suggest that memantine produced
dose-dependent effects on performance. An ANOVA of these
data revealed a significant effect of dose (F(4,55) ⫽ 11.23; p ⫽
0.0005). A subsequent pairwise comparison showed that the rats
in the 20 mg/kg memantine group took significantly longer to
initiate movement out of the square ( p ⫽ 0.0005) compared with
the saline controls (Fig. 4a). The beam test included the most
sensitive measures for detecting drug effects. For example, latency to fall from the beam (Fig. 4b) was also found to be dependent on the dose of memantine administered (F(4,55) ⫽ 6.69; p ⫽
0.0005). The 2.5, 5, and 10 mg/kg doses of memantine decreased
latency to fall from the beam to approximately equivalent levels.
The 2.5 and 5.0 mg/kg memantine groups were each significantly
different from saline controls ( p ⫽ 0.010 and 0.008, respectively). Latencies were slightly longer and more variable for the 10
mg/kg memantine group but were not significantly different. In
contrast, there were profound differences in latencies to fall between the 20 mg/kg memantine group and saline controls ( p ⫽
0.0005). A somewhat similar dose dependency was found for
performance scores during the beam test (F(4,55) ⫽ 14.79; p ⫽
0.0005). The 5, 10, and 20 mg/kg memantine groups showed
significantly lower scores when each was compared with saline
controls ( p ⫽ 0.0005). With the exception of the animals treated

with 20 mg/kg memantine, the platform and 90° inclined screen
tests seemed to be the least sensitive in detecting differences between treatment groups (Fig. 4d,e). Although a significant effect
of dose was found for both measures (F(4,55) ⫽ 9.43, p ⫽ 0.0005
and F(4,55) ⫽ 12.74, p ⫽ 0.0005, respectively), subsequent pairwise comparisons showed that these effects were predominantly
attributable to the poor performance of the 20 mg/kg memantine
group ( p ⫽ 0.0005) relative to the saline controls because the
performance of all of the other memantine groups was not different from that of the saline controls. All of the groups also
performed similarly during the inclined screen test, except for the
20 mg/kg memantine group, in which all of the rats were unable
to remain on the screen long enough to climb to the top of the
apparatus and thus were given maximal scores of 60 s.
Side effects index
Compiling the results from the activity and sensorimotor tests to
generate a side effects index resulted in a continuum of dosedependent side effects from memantine administration (Fig. 4f ).
At one end of the continuum, the 20 mg/kg dose produced side
effects on every measure studied, whereas at the other end of the
continuum, the 2.5 mg/kg dose produced side effects in only one
of the eight measures. The 5 and 10 mg/kg doses of memantine
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Table 2. ANOVA summaries from dose–response and state-dependent hole-board experiments
Effects
Dose–response
Dose
Test session
Dose ⫻ test session
Acquisition
Retention
Sal versus 2.5 Mem
Sal versus 5.0 Mem
Sal versus 10.0 Mem
State-dependent
Drug (Sal vs Mem)
Drug ⫻ test session
Acquisition
Retention

df

F
(trials/errors)

3, 50
1, 50
12, 135
1, 50
1, 50
1, 50
1, 50
1, 50

2.39/1.36
242.88/213.20
11.44/9.64
0.59/0.61
19.53/19.32
4.15/2.47
13.53/7.98
56.31/56.46

1, 14
1, 14
1, 14
1, 14

5.55/4.18
15.74/1.50
0.07/0.58
26.59/30.80

*p ⬍ 0.017, **p ⬍ 0.025, Bonferroni’s corrected levels. Mem, Memantine; Sal, saline.

Figure 5. Effects of memantine on hole-board acquisition and retention performance. a,
Hole-board acquisition (spatial learning) performance was not impaired by any of the three
doses (2.5, 5, and 10 mg/kg) of memantine (Mem) administered before testing. Testing 24 h
later revealed a dose-dependent impairment in retention performance for animals treated with
5 or 10 mg/kg doses of memantine. b, The same pattern of results was found for acquisition and
retention with regard to errors committed in reaching criterion. c, The cumulative percentage of
animals reaching criterion as a function of blocks of trials shows group performances over the
posttreatment period, during which time very similar acquisition rates were observed for all of
the groups. d, In contrast, the animals that received the 5 or10 mg/kg doses of memantine
before acquisition testing exhibited slower rates to reach criterion during retention when tested
24 h later. *p ⬍ 0.017, Bonferroni’s corrected level; †p ⬍ 0.05.

produced intermediate levels of side effects that were fourfold to
threefold less than that observed after the 20 mg/kg dose.
Hole-board testing of spatial learning and memory
The 20 mg/kg dose of memantine induced such gross behavioral
disturbances that the rats could not be tested on the hole board
after administration of this dose. Treatment with memantine at
lower doses preceding acquisition trials on day 1 of hole-board
testing induced lethargy, ataxia, and slowed movements in some
animals such that some were excluded from additional testing for

failure to perform (for description of the a
priori criterion for exclusion attributable
to nonperformance, see Materials and
Methods). Twenty-six percent (5 of 19) of
animals in the 10 mg/kg group and 25% (3
0.08/0.26
of 12) of animals in the 5 mg/kg group
0.0005
were excluded from acquisition testing on
0.0005
day 1 for failure to perform after meman0.62/0.61
0.0005**
tine treatment. No animals were excluded
0.05/0.12
from the saline or 2.5 mg/kg memantine
0.001*/0.007*
groups. The animals remaining in each
0.0005*
group for statistical analyses were as follows: saline (n ⫽ 10) and memantine at 2.5
0.03/0.026
mg/kg (n ⫽ 10), 5 mg/kg (n ⫽ 9), and 10
0.001/0.24
mg/kg (n ⫽ 14).
0.80/0.46
An overall ANOVA conducted on the
0.0005**
acquisition and retention trials-tocriterion data revealed a significant main
effect of test session (acquisition vs retention) and a significant dose ⫻ test session interaction (Table 2),
showing that the animals generally performed better during retention compared with acquisition suggesting some learning had
occurred, although the degree of learning depended on the type
of treatment (memantine vs saline). An ANOVA conducted on
the acquisition data (day 1) yielded a nonsignificant effect of
dose, showing that spatial learning was not impaired by memantine at any dose (2.5, 5, or 10 mg/kg) (Fig. 5a). In contrast, an
ANOVA performed on the retention data from day 2 indicated
that groups differed significantly in terms of performance, and
subsequent pairwise comparisons indicated that this was mostly
attributable to both the 5 and 10 mg/kg memantine groups being
significantly impaired compared with saline controls ( p ⫽ 0.001
and 0.0005, respectively). Impairment of memory retention was
clearly a dose-dependent effect. That is, the degree of retention
deficit demonstrable on day 2 depended on the dose of memantine administered before acquisition testing on day 1. A significant retention deficit effect ( p ⬍ 0.017, Bonferroni’s corrected)
was seen for 5 and 10 mg/kg memantine compared with saline.
The same pattern of results was found for acquisition and retention when errors committed in reaching criterion served as the
dependent variable (Table 2, Fig. 5). Group performances over
time during acquisition and retention trials are shown in Figure
5, c and d. Note that the rates of reaching criterion are very similar
for all of the groups during acquisition (Fig. 5c). In contrast, the
rates of reaching criterion (Fig. 5d) are much slower in the 5 and
10 mg/kg memantine groups compared with the saline controls
during retention trials, thus supporting the trials-to-criterion
data cited above.
p
(trials/errors)

Hole-board testing of state-dependent effects
In the experiment just described, memantine was administered
on day 1, when acquisition performance was tested, but not on
day 2, when retention was evaluated. This raises the question of
whether retention of memory for information learned under the
influence of memantine is a state-dependent phenomenon. In
other words, the information learned under the influence of memantine during acquisition trials on day 1 may be retrievable if
the rats are tested on retention (day 2) when they are also under
the influence of the drug. To evaluate this possibility, we conducted another experiment in which rats were treated with either
saline or 10 mg/kg memantine on day 1 before acquisition trials
and then received the same saline/drug treatment again on day 2
before retention testing. In this test, we found no evidence for a
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Figure 6. Testing the potential role of state dependency for retention of information acquired under the influence of memantine. Animals were treated either with saline or memantine (10 mg/kg; Mem) on day 1 before acquisition testing and also on day 2 before retention
testing. On acquisition testing, the memantine-treated animals performed as well as saline
controls with regard to both trials-to-criterion (a) and errors (b) but were significantly impaired
on both measures during retention testing. Because the same retention deficit is demonstrable,
regardless of whether the rats are or are not under the acute influence of memantine at the time
of retention testing, the retention deficit cannot be explained in terms of a state dependency
effect. *p ⬍ 0.0005.

state-dependent learning effect but rather observed the same pattern of effects that were found in the first hole-board experiment
(Fig. 6). Namely, on day 1, rats treated with 10 mg/kg memantine
acquired the information as readily as the saline controls, as we
had found previously, and this was confirmed by ANOVAs conducted on the trials-to-criterion (Fig. 6a) and error (Fig. 6b) data,
which both yielded nonsignificant drug (10 mg/kg memantine vs
saline) effects (Table 2). However, on day 2, while under the
influence of the same dose of memantine, ANOVAs conducted
on the retention data showed that the drug-treated rats exhibited
significantly impaired performance relative to the saline controls
in terms of both trials-to-criterion and the number of errors
committed during retention testing (Table 2). Group performance over time is shown in Figure 6, c and d. Similar to the
results from the previous experiment, during the acquisition testing, the memantine group reached criterion at approximately the
same rate as the saline controls (Fig. 6c), although the rate of
reaching criterion during retention testing was much slower for
the memantine group.

Discussion
Our evaluation of memantine reveals that it has properties very
similar to those of other NMDA antagonist drugs (i.e., MK-801,
PCP, and ketamine) that share the same site of action within the
NMDA receptor ion channel. In the adult rat, drugs acting at this
site characteristically disrupt memory, produce sensorimotor
disturbances, and induce distinctive behavioral stereotypies at
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doses lower than are required for neuroprotection against excitotoxic injury (Wozniak et al., 1990; Brosnan-Watters et al.,
1996). In humans, NMDA antagonists typically trigger psychotic
reactions at doses lower than are required to achieve a neuroprotective effect, and this is a major reason why drugs in this class
have not been successfully developed as neuroprotectants. In human clinical trials, efforts to escalate the dose to a neuroprotective
level have consistently resulted in intolerable side effects, resulting in the abandonment of the clinical research using this class of
drug (Herrling, 1992; Grotta et al., 1995). Although memantine
may be a substantially weaker NMDA antagonist compared with
MK-801 or PCP, its adverse side effects/neuroprotection dose
ratio is essentially identical to these agents in that it requires a
moderate dose of memantine to trigger side effects and a substantially higher dose to provide therapeutic benefits. Our results
show that, in adult rats, memantine, like other NMDA antagonists, disrupts memory and induces PCP-like stereotypies, sensorimotor disturbances, and alterations in activity at doses onequarter to one-half the dose required to provide minimal
neuroprotection. Assuming that an excitotoxic mechanism underlies the neurodegenerative process in AD, our finding that
memantine is neuroprotective against kainic acid-induced excitotoxicity qualifies memantine as a rational therapy for AD.
However, our companion observation that it provides only weak
neuroprotection at doses that produce severe sensorimotor and
memory impairments suggests that its neuroprotective potential
may be of limited practical value.
How can these findings be reconciled with claims that memantine provides protection against excitotoxic neurodegeneration in both adult rats and human AD patients at doses that are
free from side effects? In an adult rat study (Chen et al., 1998) that
is often cited by other authors (Parsons et al., 1999; Danysz and
Parsons, 2003) as evidence for the neuroprotective effects of memantine in the absence of side effects, it is reported that memantine protects against hypoxic/ischemic brain damage but has no
adverse effect on Morris water maze learning or on any other
behavioral parameter. However, the statistical analysis of behavioral data presented by Chen et al. (1998) is limited to a comparison of memantine-treated and MK-801-treated rats. No statistical comparison was made between memantine-treated and saline
control rats. They found that the learning and memory impairment induced by MK-801 was significantly greater than that induced by memantine, but they failed to address whether memantine alone impairs learning and memory. Their conclusion that
memantine lacks other behavioral side effects that NMDA antagonists are known to have was based on an anecdotal assessment
without objective measures being performed. In contrast, our
study is the first to systematically measure sensorimotor and
learning and memory effects of memantine using a comprehensive battery of tests, including a task that evaluates spatial reference memory. Our findings are consistent with previous research
with regard to the threshold for conferring neuroprotection in
that we found that a 20 mg/kg dose was required for memantine
to begin to produce an anti-excitotoxic neuroprotective effect.
However, at 20 mg/kg, there was only minimal neuroprotection,
and this was accompanied by severe disruption of neurobehavioral functions. In fact, at this dose, all of the animals showed
severe sensorimotor impairment, and, at one-half and onequarter of this dose, ⬃25% of the animals could not complete the
hole-board learning/memory task. Those that did complete the
task showed significant impairment in memory retention.
The conclusion that memantine has a higher index of therapeutic safety than other NMDA antagonists is called into ques-
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tion by our findings and by the fact that previous studies have not
adequately evaluated the neurobehavioral effects of memantine.
Theoretically, because the neuroprotective benefits and adverse
side effects of NMDA antagonist drugs are both dependent on the
degree of blockade of the NMDA receptor, it is difficult to understand how any NMDA antagonist can block the NMDA receptor
channel sufficiently to provide neuroprotection without such
blockade being sufficient to produce adverse side effects. This is
especially so because all NMDA antagonists that have been studied, including those that act at the same channel site as memantine, have been found to produce adverse side effects from lesser
degrees of NMDA receptor blockade than are required to provide
neuroprotective effects. Our findings support the conclusion that
memantine is not uniquely different from other NMDA antagonists. It produces the same types of adverse side effects, including
stereotypies and disruption of memory, as other NMDA antagonists, and it produces these effects at substantially lower doses
than are required for neuroprotection.
The suggestion that memantine, in human AD patients, can
enter the brain in concentrations sufficient to block NMDA receptors and, as a result, can selectively produce desired antiexcitotoxic beneficial effects that include improvement of cognitive functions while bypassing all side effects is inconsistent with
the bulk of research information pertaining to NMDA antagonist
drugs. Although potential species differences between rats and
humans must be taken into consideration, the argument that
memantine is uniquely more safe than other NMDA antagonists
assumes that this is the case for both rats and humans. Indeed, it
has been argued repeatedly (Chen et al., 1998; Parsons et al., 1999;
Danysz and Parsons, 2003) that, in both rats and humans, memantine is uniquely different from other NMDA receptor antagonists in having distinctly different receptor kinetics that allow it
to achieve a neuroprotective effect in either species at doses that
are totally free from side effects. Our findings raise serious questions regarding the tenability of this argument. However, even if
this argument proves untenable, this would not rule out a therapeutically beneficial effect of memantine in AD patients. Rather,
it would suggest that, if the drug confers a benefit, it is likely not
mediated though NMDA receptors. The fact that AD patients can
be given memantine at a dose of 20 mg/d without incurring any
NMDA antagonist type of side effect suggests that this dose produces concentrations of memantine in the human brain that are
below the threshold for NMDA receptor antagonism. This interpretation is consistent with data from human clinical trials of
memantine as a drug for relieving neuropathic pain. It has been
shown repeatedly in animal studies that various NMDA antagonists (Davar et al., 1991; Backonja et al., 1994), including memantine (Neugebauer et al., 1993; Eisenberg et al., 1995), if administered at a dose that blocks NMDA receptors, can relieve
neuropathic pain. In a clinical trial in which memantine was
administered to neuropathic pain patients for 9 weeks at doses
titrated to the individual patient’s level of tolerance, the maximum tolerated dose was 55 mg/d (Sang et al., 2002). This was the
dose at which subjectively determined disagreeable side effects
began to occur, but, at this dose, there was no relief of neuropathic pain. This signifies that memantine in human patients
produces adverse side effects at a dose lower than is required to
provide a therapeutic benefit that clearly depends on blockade of
NMDA receptors.
Thus, both animal and human data support the interpretation
that memantine does not produce intolerable side effects in human AD patients because it is being used at doses that are below
the threshold for interacting with NMDA receptors. This raises
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the possibility that the beneficial effects seen in AD patients may
be attributable to the interaction of memantine with other transmitter systems. In fact, in their review of the preclinical studies for
memantine as an anti-parkinsonian agent, Danysz et al. (1997)
provide extensive evidence for interactions of memantine with
dopaminergic, serotonergic, and cholinergic transmitter systems.
It has also been found recently that memantine may interact
more potently with cholinergic receptors than NMDA receptors
(Aracava et al., 2005). This is of particular interest in the context
of AD therapy in that the only approved AD therapies target the
glutamatergic and cholinergic transmitter systems, and currently
it is not uncommon for memantine (the only approved glutamatergic agent) to be administered to AD patients in combination
with approved cholinergic agents (Tariot et al., 2004).
Clearly, if our interpretation is correct, it is untenable to maintain that memantine arrests neurodegeneration in AD, or has any
other beneficial effect in AD, by blocking NMDA receptors.
Moreover, there is no clinical evidence to support the notion that
memantine arrests neurodegeneration in the human condition of
AD. If memantine is truly beneficial in AD, and the benefit is not
mediated by NMDA receptor blockade, it would be wise to shift
emphasis away from the NMDA receptor and intensify research
efforts to determine the real mechanistic basis for this beneficial
effect with an aim toward developing new drugs that are safer and
more effective.
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